Clinical trial

Lorlatinib in ROS1+ NSCLC With Brain Metastasis

NCT07083687

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2025-08-15

PhasePHASE2

Study timeline

Study start (estimated)2025-08-15Date precision: day

Registry last updated2025-07-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Lung Cancer (NSCLC)unresolved

Interventions

Lorlatinib 100 mgDRUG · verified · RxNorm: lorlatinib 100 MG

Sponsors & collaborators

Hunan Cancer Hospitallead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07083687 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.